CORRELATIVE SCIENCE CORE
相关科学核心
基本信息
- 批准号:10220874
- 负责人:
- 金额:$ 2.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-19 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaApoptosisBiological AssayBiostatistics CoreCLIA certifiedCancer CenterCellsClinicalClonal EvolutionDataDevelopmentDiagnosisEnvironmentGenesGoalsHRX proteinHeterogeneityHistopathologyHumanImmuneInfrastructureMeninMitochondriaMutationMyeloproliferative diseaseNPM1 genePatientsPre-Clinical ModelProteinsRNAReproduction sporesResearch PersonnelSYK geneSamplingScienceSensitivity and SpecificityServicesSignal PathwaySpecialized CenterSpliceosomesTestingTherapeutic AgentsTranslatingWorkXenograft procedurebasedesignimmune checkpointinhibitor/antagonistinnovationleukemiamolecular markermutational statusneoplastic cellnext generation sequencingnovel therapeuticspredicting responseprotein biomarkersresearch clinical testingresponsesuccesstargeted treatment
项目摘要
The major goals of Core 3 are to provide the SPORE with the infrastructure and professional expertise needed
to develop, validate, and implement molecular biomarker tests on patient samples and xenografted human
leukemias. These tests will be used to characterize the response of myeloid neoplasms obtained from patients
and preclinical models to targeted therapies being tested in each of the projects. The Core is led by Dr. Jon C.
Aster, a senior leukemia investigator and practicing hematopathologist. Tests will be carried out in the Core will
include assays that gauge NPM1 and DNMT3A mutational status (Project 1), SYK activation (Project 2),
mutational status of genes encoding spliceasome components and SF3B1 inhibition (Project 3), and the
expression of immune checkpoint proteins (Project 4). The Core will also perform serial NextGen Sequencing
to determine the effect of targeted therapy on clonal dynamics, and develop new tests that assess the
sensitivity of tumor cells to apoptosis (BH3 profiling/mitochondrial priming), or that predict and gauge the
response of neoplastic cells to SYK inhibitors, Menin/MLL inhibitors, and other targeted therapeutics.
The specific aims of the Core are:
1) To use a clinically validated amplicon-based NextGen sequencing test to identify mutations, define
clonal heterogeneity, and follow the clonal evolution of myeloid neoplasms during therapy
2) To develop, validate, and implement tests for phospho-SYK, immune checkpoint proteins, lineage-
specific host immune cell markers, and other protein biomarkers
3) To develop, validate, and implement RNA profiling-based tests that identify signatures of effective
targeting of leukemogenic signaling pathways with novel therapeutic agents, including spliceasome
inhibitors, and Menin/MLL inhibitors
4) To develop, validate, and implement a BH3 profiling/mitochondrial priming assay to predict the
response of myeloid neoplasms to targeted therapeutics
Core 3的主要目标是为SPORE提供所需的基础设施和专业知识
开发,验证和实施对患者样本和异种移植人的分子生物标志物测试
白血病这些检测将用于描述从患者中获得的骨髓肿瘤的反应
和临床前模型的靶向治疗正在测试中的每一个项目。核心由Jon C博士领导。
高级白血病研究员和执业血液病理学家。测试将在核心区进行,
包括测定NPM 1和DNMT 3A突变状态(项目1)、SYK激活(项目2)
编码剪接体组分和SF 3B 1抑制的基因的突变状态(项目3),以及
免疫检查点蛋白的表达(项目4)。核心还将执行系列NextGen测序
确定靶向治疗对克隆动力学的影响,并开发评估克隆动力学的新测试
肿瘤细胞对凋亡的敏感性(BH 3谱/线粒体引发),或预测和衡量肿瘤细胞对凋亡的敏感性。
肿瘤细胞对SYK抑制剂、Menin/MLL抑制剂和其他靶向治疗剂的反应。
该核心的具体目标是:
1)为了使用临床验证的基于扩增子的NextGen测序检测来识别突变,定义
克隆异质性,并在治疗期间跟踪髓系肿瘤的克隆演变
2)开发、验证和实施磷酸化SYK、免疫检查点蛋白、谱系-
特异性宿主免疫细胞标志物和其它蛋白质生物标志物
3)开发,验证和实施基于RNA分析的测试,以识别有效的
用包括剪接体在内的新治疗剂靶向致白血病信号通路
抑制剂和Menin/MLL抑制剂
4)开发、验证和实施BH 3分析/线粒体引发试验,以预测
髓系肿瘤对靶向治疗的反应
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JON C. ASTER其他文献
JON C. ASTER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JON C. ASTER', 18)}}的其他基金
Pre-cancer atlases of cutaneous and hematologic origin (PATCH Center)
皮肤和血液来源的癌前图谱(PATCH 中心)
- 批准号:
10252281 - 财政年份:2018
- 资助金额:
$ 2.05万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 2.05万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 2.05万 - 项目类别:
Discovery Grants Program - Individual